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Abstract
Background: Vascular complications occurring during cisplatin-based chemotherapy of germ cell
tumours are inadequately recognized to date.
Case Presentation: A 49 year old man with advanced seminoma underwent two courses of
chemotherapy according to the PEB regimen. Upon restaging, two thrombotic deposits were noted
in the descending part of the thoracic aorta and in the infrarenal abdominal aorta, respectively.
Although thrombotic plaques caused aortic occlusion of about 30%, no clinical signs of malperfusion
of limbs were registered. The patient was placed on anticoagulant therapy. Six months after
completion of chemotherapy, thrombotic deposits had completely resolved. In the absence of
other predisposing factors, it must be assumed that cisplatin-based chemotherapy represented a
strong stimulus for arterial thrombosis in the aorta.
Conclusions: This is the first case of endo-aortic thrombosis during chemotherapy for testicular
germ cell cancer. Providers of chemotherapy must be aware of arterial thrombosis even in young
patients with testicular cancer.
Background
Cis-platin based chemotherapy is the cornerstone in the
management of metastatic testicular germ cell tumour
(TGCT) [1]. The regimen consisting of cisplatin, etoposide
and bleomycin (PEB) is usually well tolerated, yet, the tox-
icity profile of this procedure is significant [2]. Basically,
there are acute (immediate) and chronic (late) untoward
effects of the PEB protocol. Second malignancies and car-
diovascular events constitute well recognized long-term
hazards of this chemotherapy [3]. With regard to late car-
diovascular problems, cisplatin is thought to initiate
degenerative processes of vessel walls, thus causing occlu-
sive vascular disease in the long run. All types of arteries
may be involved, and accordingly, there is sound evidence
for an excess of myocardial infarctions, arterial hyperten-
sion, and cerebral strokes occurring in TGCT patients dur-
ing long-term follow-up. Only recently it became
apparent that cardiovascular complications secondary to
cisplatin-based chemotherapy may also occur early during
the application of systemic therapy or immediately there-
after [4]. Such complications from cisplatin-based chem-
otherapy have been encountered in several malignancies
[5,6]. However, these events are not well recognized
among TGCT patients who are usually younger than most
of the patients with other solid malignancies. Thus, we
report an unusual case with endo-aortic thrombosis
occurring during chemotherapy.
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Case presentation
A 49 year old patient presented with advanced seminoma
by bulky retroperitoneal disease and left-sided supracla-
vicular lymphadenopathy, corresponding to stage III
(Lugano classification) and to the good prognosis group
according to IGCCCG [1], respectively. History involved
surgical occlusion of patent Ductus arteriosus Botalli at
the age of 17 years. During adult life, no cardiovascular
problems had been encountered, clinically. Correspond-
ingly, no major vascular anomaly had been detectable
upon staging CT (Fig. 1a, b). Two cycles of chemotherapy
according to the PEB regimen were administered in full
dose. Clinical course was uneventful. Restaging with
abdominal computed tomography (CT) of chest and
abdomen revealed regression of metastases and, unex-
pectedly, endo-aortic thrombotic deposits in the descend-
ing arch of the thoracic aorta (Fig. 2a) close to the former
junction of aorta and Ductus arteriosus. Surprisingly,
another thrombotic deposit was found in the infrarenal
abdominal aorta (Fig. 2a, b). As documented in the pri-
mary staging CT, these changes had not been present prior
to chemotherapy (Fig. 1). Although the abdominal aorta
was occluded to approximately 30% by thrombotic mate-
rial, no significant clinical symptoms were noted by the
patient. Anticoagulant treatment with low-molecular
heparin and acetylic salicylic acid was instituted. Then, the
third cycle of chemotherapy was applied in full dose and
without delay. Final restaging after completion of chemo-
therapy revealed regression of metastases and partial
regression of thrombotic deposits at the thoracic and
abdominal endo-aortic walls. Anticoagulant therapy was
changed to oral warfarin as a permanent medication. Six
months later, CT revealed complete resolution of throm-
botic material at the thoracic aorta and only minor resid-
ual thickening of the abdominal aortic wall (Figs. 3a, b).
Discussion
Endo-aortic thrombosis is a quite exceptional complica-
tion of cisplatin-based chemotherapy. Only few cases
have been reported to date involving patients with
esophageal carcinoma [7], cervical cancer [8], pancreatic
carcinoma and malignant lymphoma [9]. With respect to
testicular germ cell tumour, the present case is probably
the first event of an endo-aortic thrombosis occurring dur-
ing chemotherapy. Verdonk et al. reported a celiac trunk
thrombosis in a patient undergoing chemotherapy for
TGCT [10]. Thrombotic occlusion of peripheral arteries
during chemotherapy have been reported in a number of
TGCT patients [11-13].
According to Virchow's classical theory, thrombogenesis
is principally precipitated by three conditions, first, by
compromised blood flow, second, by increased ability of
the internal vessel wall to attract blood cells, and third, by
systemically increased clotting tendency (humoral fac-
tors). Clotting at the aortic wall may arise in the presence
of abdominal aortic aneurysm and in extensive athero-
sclerotic disease, respectively.
Contrast enhanced CT-scan at the time before onset of chemotherapy Figure 1
Contrast enhanced CT-scan at the time before onset of chemotherapy. 1a: Chest CT. patent aorta, no thrombotic 
deposits. 2a: abdominal CT: patent aorta, no thrombotic deposits. Minor calcifications in the aortic wall, no major atheroscle-
rotic signs. Note: metastatic deposits around the abdominal aorta; larger metastatic mass located cranial to this section (not 
shown).BMC Cancer 2009, 9:459 http://www.biomedcentral.com/1471-2407/9/459
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Our patient is 49 years old which represents an age cate-
gory clearly beyond the median age of TGCT patients. As
thrombosis is generally associated with increasing age, a
slightly increased risk of thrombosis must therefore be
considered for this individual, basically. Moreover, he
used to be a smoker and there were some minor calcifica-
tions detectable in the infrarenal aortic wall upon staging
CT. However, there was no clinical sign of systemic
atherosclerosis, the body mass index was within normal
range (24.8 kg/m2), and no other vascular risk factors
were revealed upon clinical examination. Thus in all,
there was no rationale to consider any compromised aor-
tic blood flow as a pre-existing risk for thrombosis in this
patient.
A tempting idea would be to consider the site of the oper-
ative occlusion of the Ductus arteriosus Botalli as an area
of increased risk of blood cell adhesions. However, this
view must remain rather hypothetical because this puta-
tive nidus for thrombotic adhesion had been present for
Contrast enhanced CT-scan after 2 cycles of chemotherapy Figure 2
Contrast enhanced CT-scan after 2 cycles of chemotherapy. 2a: Chest CT: thrombotic deposit in the descending arch 
of thoracic aorta (arrow). 2b: abdominal CT: extensive endo-aortic thrombosis (arrow).
Restaging CT during follow-up Figure 3
Restaging CT during follow-up. Anticoagulant therapy had been applied for 6 months. 3a: Chest CT: complete resolution 
of thrombus (arrow). 3b: abdominal CT: almost complete regression of endo-aortic thrombosis (arrow). Only minor thicken-
ing of aortic wall.BMC Cancer 2009, 9:459 http://www.biomedcentral.com/1471-2407/9/459
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more than 30 years without giving rise to blood cell adhe-
sions ever since. Moreover, the critical site at the wall of
the thoracic aorta would hardly explain additional down-
stream thrombotic deposits. Most obviously, chemother-
apy constituted a strong stimulus for the forming of
arterial thrombosis in our patient. Cisplatin-related
hypercoagulability would correspond to condition No. 3
according to Virchow's theory, i.e. increased (systemic)
clotting tendency of the blood caused by humoral factors.
The assumption of chemotherapy-related formation of
thrombosis is generally in accord with both, findings on
the laboratory level e.g. increased levels of von Willebrand
factor and other thrombosis-associated factors in patients
receiving cisplatinum [14,15] as well as with cisplatin-
induced hypomagnesemia and with clinical observations
of arterial thromboses and even myocardial infarctions in
TGCT patients undergoing chemotherapy [4]. Notwith-
standing, the formation of thrombotic plaques in the ves-
sel with highest volume-throughput of the body
represents a mostly striking observation.
Conclusion
Providers of TGCT chemotherapy should be aware of the
hazard of arterial thromboses even in large vessels.
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